SUTRO BIOPHARMA INC (STRO) Stock Fundamental Analysis

NASDAQ:STRO • US8693672011

18.94 USD
+0.52 (+2.82%)
Last: Feb 23, 2026, 09:38 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, STRO scores 1 out of 10 in our fundamental rating. STRO was compared to 521 industry peers in the Biotechnology industry. STRO has a bad profitability rating. Also its financial health evaluation is rather negative. STRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • STRO had negative earnings in the past year.
  • In the past year STRO has reported a negative cash flow from operations.
  • In the past 5 years STRO always reported negative net income.
  • STRO had negative operating cash flow in 4 of the past 5 years.
STRO Yearly Net Income VS EBIT VS OCF VS FCFSTRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

  • STRO's Return On Assets of -103.18% is on the low side compared to the rest of the industry. STRO is outperformed by 76.01% of its industry peers.
Industry RankSector Rank
ROA -103.18%
ROE N/A
ROIC N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
STRO Yearly ROA, ROE, ROICSTRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for STRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STRO Yearly Profit, Operating, Gross MarginsSTRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • STRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for STRO has been increased compared to 1 year ago.
  • The number of shares outstanding for STRO has been increased compared to 5 years ago.
  • There is no outstanding debt for STRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STRO Yearly Shares OutstandingSTRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
STRO Yearly Total Debt VS Total AssetsSTRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -6.91, we must say that STRO is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of STRO (-6.91) is worse than 65.26% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -6.91
ROIC/WACCN/A
WACC8.76%
STRO Yearly LT Debt VS Equity VS FCFSTRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

  • STRO has a Current Ratio of 2.53. This indicates that STRO is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.53, STRO is not doing good in the industry: 70.63% of the companies in the same industry are doing better.
  • A Quick Ratio of 2.53 indicates that STRO has no problem at all paying its short term obligations.
  • The Quick ratio of STRO (2.53) is worse than 68.52% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 2.53
STRO Yearly Current Assets VS Current LiabilitesSTRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • STRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -62.11%.
  • STRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.36%.
  • STRO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.74% yearly.
EPS 1Y (TTM)-62.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.56%
Revenue 1Y (TTM)-34.36%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%13.77%

3.2 Future

  • STRO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.20% yearly.
  • Based on estimates for the next years, STRO will show a very negative growth in Revenue. The Revenue will decrease by -10.65% on average per year.
EPS Next Y26.06%
EPS Next 2Y16.98%
EPS Next 3Y15.45%
EPS Next 5Y14.2%
Revenue Next Year68.12%
Revenue Next 2Y-13.44%
Revenue Next 3Y-5.27%
Revenue Next 5Y-10.65%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
STRO Yearly Revenue VS EstimatesSTRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
STRO Yearly EPS VS EstimatesSTRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for STRO. In the last year negative earnings were reported.
  • Also next year STRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STRO Price Earnings VS Forward Price EarningsSTRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STRO Per share dataSTRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

  • STRO's earnings are expected to grow with 15.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.98%
EPS Next 3Y15.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • STRO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUTRO BIOPHARMA INC

NASDAQ:STRO (2/23/2026, 9:38:06 AM)

18.94

+0.52 (+2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners67.08%
Inst Owner Change-86.57%
Ins Owners0.88%
Ins Owner Change2.34%
Market Cap161.37M
Revenue(TTM)105.65M
Net Income(TTM)-216.32M
Analysts76.25
Price Target34.53 (82.31%)
Short Float %7.28%
Short Ratio4.61
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.69%
Min EPS beat(2)-58.49%
Max EPS beat(2)65.88%
EPS beat(4)1
Avg EPS beat(4)-5.93%
Min EPS beat(4)-58.49%
Max EPS beat(4)65.88%
EPS beat(8)4
Avg EPS beat(8)23.18%
EPS beat(12)5
Avg EPS beat(12)15.16%
EPS beat(16)6
Avg EPS beat(16)11.81%
Revenue beat(2)2
Avg Revenue beat(2)171.27%
Min Revenue beat(2)4.07%
Max Revenue beat(2)338.47%
Revenue beat(4)4
Avg Revenue beat(4)101.55%
Min Revenue beat(4)4.07%
Max Revenue beat(4)338.47%
Revenue beat(8)7
Avg Revenue beat(8)153.84%
Revenue beat(12)9
Avg Revenue beat(12)100.79%
Revenue beat(16)11
Avg Revenue beat(16)82.65%
PT rev (1m)0%
PT rev (3m)1160.64%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)-959.51%
EPS NY rev (1m)0.06%
EPS NY rev (3m)-1032.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-7.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.53
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26.1
EYN/A
EPS(NY)-19.08
Fwd EYN/A
FCF(TTM)-26.45
FCFYN/A
OCF(TTM)-26.15
OCFYN/A
SpS12.4
BVpS-10.24
TBVpS-10.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -103.18%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 34.1%
Cap/Sales 2.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.53
Quick Ratio 2.53
Altman-Z -6.91
F-Score2
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)81.45%
Cap/Depr(5y)145.34%
Cap/Sales(3y)6.47%
Cap/Sales(5y)12.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.56%
EPS Next Y26.06%
EPS Next 2Y16.98%
EPS Next 3Y15.45%
EPS Next 5Y14.2%
Revenue 1Y (TTM)-34.36%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%13.77%
Revenue Next Year68.12%
Revenue Next 2Y-13.44%
Revenue Next 3Y-5.27%
Revenue Next 5Y-10.65%
EBIT growth 1Y-4.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.25%
EBIT Next 3Y18.5%
EBIT Next 5YN/A
FCF growth 1Y-44.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.98%
OCF growth 3YN/A
OCF growth 5YN/A

SUTRO BIOPHARMA INC / STRO FAQ

What is the ChartMill fundamental rating of SUTRO BIOPHARMA INC (STRO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to STRO.


What is the valuation status for STRO stock?

ChartMill assigns a valuation rating of 0 / 10 to SUTRO BIOPHARMA INC (STRO). This can be considered as Overvalued.


Can you provide the profitability details for SUTRO BIOPHARMA INC?

SUTRO BIOPHARMA INC (STRO) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SUTRO BIOPHARMA INC?

The Earnings per Share (EPS) of SUTRO BIOPHARMA INC (STRO) is expected to grow by 26.06% in the next year.